Asperger's Disorder, Autism, Autistic Disorder, PDD, Pervasive Developmental Disorder
Conditions
Keywords
Autism, Autism spectrum, Autism children
Brief summary
If autism is the consequence of a chronic inflammatory process preventing the infant brain from forming the proper neural connections, then treatment that reduces inflammation might have a positive impact on autism. IGIV treatment has been known to suppress inflammation and has been used in the treatment of inflammatory conditions and autoimmune diseases.
Detailed description
We have come to believe that an immature immune system with abnormal signaling and altered apoptotic pathways may result in a process of neuroinflammation with a clinical presentation of Autism Spectrum Disorder. If Autism Spectrum Disorders are the consequence of a chronic inflammatory process that prevents the infant brain from forming the proper neural connections, then treatment that reduces inflammation might have a positive impact on autism. We believe that there is a correlation between immunological abnormalities and the development of the autism.
Interventions
DRUGGammaplex 5%
Sponsors
Bio Products Laboratory
Isaac Melamed
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
* The subject is between the ages of or equal to 4 and 12 years of age, of either gender, and belonging to any ethnic group. * The subject has a diagnosis, for a minimum of 6 months prior to screening, of either autistic disorder, Asperger disorder, or pervasive developmental disorder (PDD). * Normal physical test results. * Immunological lab results showing reduced levels of activated CD40L or abnormal lymphocyte stimulation, or T or B cell dysfunction (hypgammaglobulinemia, primary immunodeficiency (PIDD), or common variable immune deficiency (CVID).
Exclusion criteria
* A diagnosis of isolated IGA deficiency * Allergic reactions to blood products
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary objective is to assess the efficacy of Gammaplex as an immunomodulatory therapy in autistic children with evidence of immune dysfunction. | 1 year | The primary endpoint is disease improvement, as evidenced by standardized test measures across 3 intervals: screening for baseline measurements, visit 5, and end of study visit measurements. Primary efficacy variables will be measured using the following standardized tests 1. Caregiver Scales (SRS, CCC-2, ABC) 2. CGI-S and CGI - I 3. PPVT 4. ADOS |
Secondary
| Measure | Time frame |
|---|---|
| The modulatory effect of IVIG on neuroinflammation will be assessed by laboratory measurements which we believe are indicative of immune dysregulation. | 1 year |
Other
| Measure | Time frame |
|---|---|
| To improve development in autistic spectrum | 1 year |
Countries
United States
Outcome results
None listed